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Summary Objective: Clinical parameters that predict outcome in non-immunosup-
pressed candidemic patients are not fully understood.
Methods: Eighty-one consecutive episodes of candidemia were retrospectively eval-
uated in 75 patients during 1998—2000.
Results: Infection due to Candida albicans was common (n = 30; 37%) followed by
Candida glabrata (n = 25; 31%), Candida parapsilosis (n = 14; 17%), Candida trop-
icalis (n = 6; 7%), Candida krusei (n = 5; 6%), and Candida lusitaniae (n = 1; 1%).
Among 70 evaluable patients, 31 (44%) had fungemia-associated mortality; advanced
age (P < 0.004), underlyingmalignancy (P < 0.025), coronary artery disease (P < 0.01),
and concurrent non-Candida species fungal infection (P < 0.047) were signiﬁcant
prognosticators of compromised short-term survival by multivariate analysis. Mortal-
ity was higher in patients with Candida glabrata (60%) and C. tropicalis (75%) infection
compared to 44% deaths in individuals with C. albicans infection (P>0.1). 11/25 (44%)
of non-immunocompromised individuals died and 20/45 (44%) immunosuppressed pa-
tients succumbed to fungemia: persistent vs. non-persistent (<3 days) Candida blood-
stream invasion, neutropenia, diabetes mellitus, renal insufﬁciency, prior antimicro-
bial therapy, cirrhosis of liver, abdomino-pelvis surgery, and critical-care-unit vs. non
critical-care-unit admission did not signiﬁcantly impact outcome in either group. All
11 infants, including nine with prematurity survived Candida species bloodstream
infection (P < 0.025).
Conclusions: Short-termmortality in candidemic non-immunocompromised patients
was comparable to fungemia-associated deaths in immunosuppressed patients. Is-
chemic heart disease has appeared as a new predictor of unfavorable outcome in
patients with hematogenous candidiasis.
© 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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Introduction
Candidemia is a serious complication in patients
undergoing treatment for cancer.1,2 In hospitalized
non-oncology patients, admission to a medical or
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surgical critical care unit increases the risk of sys-
temic yeast invasion,3,4 especially in the setting of
recent surgery, hyperalimentation, or acute renal
failure.3 This rise in hematogenous candidiasis5,6
is in part attributed to the near universal use of
implantable and semi-implantable indwelling in-
travascular devices7,8 and prolonged appropriate
and/or inappropriate broad-spectrum antimicro-
bial therapy with vancomycin, imipenem, etc.
given pre-emptively or empirically to susceptible
individuals.9
In fungemic cancer patients, predictors of un-
favorable outcome include prolonged and severe
granulocytopenia, multi-organ yeast dissemina-
tion, advanced malignancy, leukemia, hematopoi-
etic stem cell transplantation and intensive care
unit stay at the time of fungemia diagnosis.10—12
However, in non-immunosuppressed patients, pre-
dictors of short-term survival with candidemia are
less certain. In this retrospective evaluation, we
analyzed host- and microorganism-associated pre-
dictors of short-term survival in immunocompro-
mised and non-immunosuppressed patients with
blood-borne candidiasis.
Materials and methods
Study design
All consecutive episodes of Candida species blood-
stream invasion were evaluated from 1 January
1998 to 1 January 2000. Patient and laboratory
information was retrieved from patients’ charts
and the computerized hospital data system. All
blood culture specimens were processed at the
Microbiology Laboratory, Department of Pathology,
Palmetto-Richland Memorial Hospital, South Car-
olina, United States. Candida species isolation and
identiﬁcation was performed by methods described
elsewhere.13
Deﬁnitions
Candidemia was deﬁned as a clinical illness associ-
ated with the presence of Candida species in the
patient’s bloodstream. All positive blood cultures
for Candida species during the same hospitalization
were considered as a single episode. If more than
one Candida species was isolated, infection due to
each was considered as a separate episode.13 Per-
sistent or sustained fungemia was deﬁned as blood
isolation of yeast for >3 days.13—15
Neutropenia was deﬁned as either absolute neu-
trophil count <500 cells/l, or total white cell
count of <1000 cells/l; severe neutropenia and
granulocytopenia are used interchangeably. Pa-
tients with underlying malignancy, hematopoietic
stem cell transplantation, neutropenia, and/or
prolonged (>2 weeks) systemic corticosteroid ther-
apy were considered immunosuppressed. Advanced
age was deﬁned as >55 years.
Fungemia-associated mortality was deﬁned as
death within 30 days of initial blood culture yeast
isolation, and absence of known terminal events,
such as intracranial or gastrointestinal hemorrhage
or pulmonary embolism.1,13
Fungemia, candidemia, hematogenous candidia-
sis, blood-borne candidiasis and Candida species
bloodstream invasion are used interchangeably.
Statistical analysis
In the univariate analysis, the Pearson 2 test was
used to compare categorical variables in patients
with fungemia. For the multivariate analysis, a lo-
gistic regression was employed to compare categor-
ical and continuous populations. A comparison was
declared signiﬁcant if the P value was <0.05.
Results
Patient and disease characteristics
Patient characteristics are presented in Table 1.
Eighty-one episodes of fungemia occurred in 75 pa-
tients; 69 individuals (92%) had infection due to a
single Candida species and in six patients (8%) mul-
tiple yeast species were isolated from blood culture
samples. Candida albicans was common (n = 30;
37%); in 51 (63%) episodes due to non-albicans can-
didemia, nearly half had C. glabrata (n = 25; 49%)
hematogenous invasion, followed by C. parapsilosis
(n = 14; 17%), C. tropicalis (n = 6; 7%), C. krusei
(n = 5; 6%), and C. lusitaniae (n = 1; 1%).
Among 70 evaluable patients, overall fungemia-
associated short-term mortality was 44% (n = 31).
Twenty-three of 70 patients (33%) had C. albicans
infection and ten of these (44%) died. Mortality
was 50% (1/2), 60% (12/20), and 75% (3/4) in pa-
tients with C. krusei, C. glabrata, and C. tropicalis
bloodstream infections, respectively (Table 3). In
patients with persistent or prolonged (>3 days)
yeast blood isolation, mortality was 44%, whereas
40% died in the setting of non-persistent Candida
bloodstream invasion. Similarly, in six patients (9%)
with ≥2 Candida species, fungemia mortality was
33% (n = 2) compared to 45% (n = 29) mortality in
64 patients with a single yeast species infection. A
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Table 1 Characteristics of patients with Candida species bloodstream infection during 1998 to 2000.
N (%) Mortality (%)a
Patients 75
Male 37 (49)
Female 38 (51)
Ageb
Adults (>17 y) 56 (75) 30/51 (59)
Pediatric (>1 y) 8 (11) 1/8 (13)
Infants and neonates 11 (15) 0 (0)
WBCc,d
Normal leukocyte count (4− 10× 109/L) 26/74 (35) 7/24 (29)
Neutropenia (<1× 109/L) 8/74 (11) 5/8 (63)
Leukopenia (≥1− < 4× 109/L) 9/74 (12) 5/9 (56)
Leukocytosis (>12× 109/L) 31/74 (42) 14/28 (50)
Evaluable patients 70 31/70 (44)
Single positive blood culture 25/70 (36)
Multiple site positive blood culture 45/70 (64)
Central venous cathetere 37/71 (52) 18/35 (51)
Total parentral nutrition 47/73 (64) 22/45 (49)
Fever (>100.5 ◦F) 45/70 (64) 19/43 (44)
Afebrile 25/70 (36) 12/25 (48)
Antimicrobial usef 60/71 (85) 26/60 (43)
Single antimicrobial 10 (14) 7/10 (70)
Two antimicrobials 23 (32) 8/23 (35)
Three antimicrobials 9 (13) 3/9 (33)
Four or more antimicrobials 18 (25) 8/17 (47)
Penicillins 19 (27) 6/18 (33)
Cephlosporins 42 (59) 21/41 (51)
Vancomycin 22 (31) 8/21 (38)
Carbapenem 6 (8) 0/6 (0)
Aminoglycosides 24 (34) 6/23 (26)
Fluoroquinolones 18 (25) 8/18 (44)
Trimethoprim-sulfamethoxazole 8 (11) 0/11 (0)
Clindamycin 8 (11) 0/11 (0)
Monobactam 2 (3) 0/2 (0)
Macrolides/azolides 4 (6) 0/4 (0)
Tetracyclines 1 (1) 0/1 (0)
Antifungal use 22/71 (31) 11/20 (55)
Triazole-based antifungal 15 (21) 8/14 (57)
Amphotericin B 5 (7) 3/4 (75)
Nystatin 2 (3) 0/2 (0)
a In 5 patients, ﬁnal outcome was not available and their information was excluded from the analysis of mortality;
Mortality percentage was calculated according to the number of patients that died in within 30 days of fungemia
diagnosis/number of evaluable patients within speciﬁc category.
b Median age ±SD = 48± 29 years.
c Median WBC ±SD = 10± 9× 109/L.
d WBC analysis not available for one patient.
e Central venous catheters were not routinely removed in patients with no evidence of catheter-related fungemia;
duration of CVC prior to fungemia diagnosis was median 8± 7 days.
f Antimicrobial therapy including antibiotics and antifungals that patients received within 30 days of bloodstream
Candida species isolation.
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single death (5%) occurred in 19 pediatric patients;
all 11 infants, including nine that were premature
at birth and three receiving care in neonatal ICU,
survived blood-borne candidiasis (P < 0.025).
Ten of 70 evaluable patients (14%) received ﬂu-
conazole alone within 30 days of fungemia diagno-
sis, ﬁve of these ten (50%) developed C. glabrata
infection.
Univariate analysis
In the immunosuppressed patients, higher mortal-
ity was seen in the presence of profound granulo-
cytopenia (63%), cirrhosis of liver (100%), diabetes
mellitus (67%), and prior exposure to multiple-
broad-spectrum antimicrobials (83%). In non-
immunosuppressed patients, higher mortality was
observed in the setting of persistent non-albicans
candidemia (78%), renal dysfunction (57%) and
concurrent bacteremia (53%).
Case-control analysis comparing these two pa-
tient groups is presented in Table 2, which shows
no signiﬁcant differences in outcome. Similarly,
short-term mortality in patients with C. albicans
infections was compared with outcomes in individ-
uals with non-albicans candidemia and presented
in Table 3; there was no statistically signiﬁcant
difference in short-term mortality in either group.
Table 2 Case-control analysis of predictors of survival in 70 evaluable patients with fungemia during 1998—2000.
Confounding variables Non-compromised (n = 25) Immunosuppresssed (n = 45) P value
n (%) Mortality (%) n (%) Mortality (%)
Overall mortality 11/25 (44) 20/45 (44) >0.5
Neutropenia (ANC < 500 cells/mm3) 0 (0) 0 (0) 8 (18) 5/8 (63) NC
Leukocytosis (WBC > 11 000 cells/mm3) 14 (56) 7/14 (50) 15 (33) 7/15 (47) >0.5
Fever (>100.5 ◦F) 12 (48) 4/12 (33) 31 (69) 16/31 (52) >0.1
Central venous catheter 20 (80) 10/20 (50) 41 (91) 19/41 (46) >0.5
Cancera 1 (4) 1/1 (100) 31 (69) 18/31 (58) >0.1
AIDS 0 (0) 0 (0) 2 (44) 0/2 (0) NC
Diabetes mellitus 8 (32) 4/8 (50) 6 (13) 4/6 (67) ≥0.5
Coronary artery disease 10 (40) 8/10 (80) 5 (11) 4/5 (80) >0.5
Persistent non-albicans candidemia 9 (36) 7/9 (78) 8 (18) 5/8 (63) ≥0.5
Renal dysfunction 7 (28) 4/7 (57) 5 (11) 2/5 (40) >0.5
Cirrhosis 0 (0) 0 (0) 1 (2) 1/1 (100) NC
Abdomino-pelvic surgery 11 (44) 4/11 (36) 12 (27) 7/12 (58) >0.1
Concurrent bacterial infection 17 (68) 9/17 (53) 21 (47) 9/21 (43) ≥0.5
Concurrent non-Candida fungal infection 2 (8) 1/2 (50) 4 (9) 4/4 (100) ≥0.1
Prior antifungal exposureb 3 (12) 1/3 (33) 14 (31) 7/14 (50) >0.5
Prior antibiotic exposureb 5 (20) 2/5 (40) 6 (13) 5/6 (83) ≥0.1
NC: non-calculatable.
a One patient with remote history of cancer in clinical remission was regarded as non-immunosuppressed.
b Prior antibiotic and antifungal therapy was considered in patients with antimicrobial exposure in <3 months of
fungemia diagnosis.
Multivariate analysis
A logistic regression model was employed to com-
pare discrete and continuous variables, adjusted
for the other variables in the model. Candidemic
patients with advanced age (P < 0.004), under-
lying malignancy (P < 0.025), and concomitant
non-Candida systemic mycosis (P < 0.047) had
signiﬁcantly poor outcomes. Among 15 patients
(21%) with a history of coronary artery disease,
12 (80%) died, compared to 19 (35%) deaths in
55 patients with no known history of coronary
artery disease (signiﬁcant by multivariate analysis
(P < 0.01)). All other clinical parameters shown in
Table 2, including stay in ICU did not signiﬁcantly
increase short-term mortality in these fungemic
patients.
Discussion
Systemic candidiasis has evolved as a serious com-
plication in critically ill non-immunosuppressed
patients.3,4,14,15 Most systemic yeast infections,
especially due to Candida albicans, C. tropicalis,
C. glabrata and C. krusei arise from existing en-
dogenous orointestinal microﬂora.15,16 During the
last decade, a substantial increase in non-albicans
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Table 3 Impact on short-term mortality in patients with Candida albicans versus non-albicans bloodstream
candidiasis is compared.
Fungemia episodes in 70 evaluable patients P value
N (mortality; %)
Candida albicans vs non-albicans spp. 23 (10; 44%) vs 47 (21; 45%) NS
Candida albicans vs C. glabrata 23 (10; 44%) vs 20 (12; 60%) NS
Candida albicans vs C. parapsilosis 23 (10; 44%) vs 14 (3; 21%) NS
Candida albicans vs C. tropicalis 23 (10; 44%) vs 4 (3; 75%) NS
Candida albicans vs C. krusei 23 (10; 44%) vs 2 (1; 50%) NS
Candida albicans vs ≥2 Candida species 23 (10; 44%) vs 6 (2; 33%) NS
One patient with C. lusitaniae infection who died is not included in comparative Candida species analysis, although
he is included in the overall analysis of C. albicans versus non-albicans candidemia. N is the number of patients
with each organism; in parenthesis the number of patients that died and the percentage of patients in whom
mortality was associated with speciﬁc Candida species is presented. NS = not signiﬁcant.
Candida species infection in oncology patients
and those with acquired immune deﬁciency syn-
drome was, in part, attributed to a shift in colo-
nizing yeast species resulting from triazole-based
antifungal-induced selection of less-susceptible
microorganisms.13,17—20 A similar pattern of Can-
dida species shift was recently observed in crit-
ically ill, non-immunosuppressed hospitalized
patients.14,21 In this report, nearly one-third (31%)
of bloodstream infections were due to C. glabrata,
an observation consistent with current species
re-distribution trends observed in the USA,17 albeit
most of our patients with C. glabrata infections
did not receive prior ﬂuconazole therapy.17,22,23
It was interesting to note that recent exposure
(<30 days) to ﬂuconazole was seen in one-quarter
(5 of 20) of patients with C. glabrata fungemia,
but only 10% (5/50) of patients with non-glabrata
candidemia, although this difference was not sig-
niﬁcant (P>0.1).
Advanced age, underlying malignancy and con-
comitant non-Candida fungal infections were asso-
ciated with increased fungemia-associated deaths
in our group, which was in concert with adverse
prognosticators noted in oncology patients.10—12
The presence of coronary artery or ischemic heart
disease appeared as a new predictor in patients
with signiﬁcantly compromised short-term survival
with systemic candidiasis. Existing ischemic heart
disease is a well-recognized co-morbidity, which
predicts compromised survival in patients with
serious systemic infections; this association in pa-
tients with candidemia was not unexpected. The
presence of leukocytosis, fever, central venous
catheter and prior exposure to antifungal drugs
were not associated with a signiﬁcant negative
impact on survival in either group. It was encour-
aging to note that candidemia-related mortality in
the pediatric population was markedly low (5%),
compared to 44% mortality in adult patients with
hematogenous candidiasis.
The signiﬁcant difference in response among
all high-risk candidemic infants including those
with prematurity (P < 0.025) was probably as-
sociated with intact peripheral blood neutrophil
count, absence of prolonged exposure to multiple
broad-spectrum antimicrobials, in some, prompt re-
moval of infected indwelling intravascular catheter,
and appropriate therapeutic intervention.
In patients with persistent-prolonged fungemia,
mortality (44%) was comparable to candidemia-
related deaths (40%) in the non-sustained
setting.24,25 Similarly, mortality was comparable
in patients with C. albicans infection (44%); the
higher death rates seen in patients with C. glabrata
(60%) and C. tropicalis (75%) infection were not
signiﬁcantly different from fungemia outcome in
patients with C. albicans infection (P>0.1). Sys-
temic C. albicans dissemination is often a severe
illness, compared to hematogenous invasion due to
non-albicans Candida species, including C. parap-
silosis, and C. glabrata.26—28 This observation was
reproduced in animal studies; systemic C. albicans
infection resulted in fulminant and universally fa-
tal disease in untreated non-immunosuppressed
animals, whereas a sub-acute, non-fatal infection
was commonly observed in animals infected with
C. glabrata.29
Conclusion
In conclusion, hematogenous candidiasis was
a serious complication associated with compa-
rably high mortality in non-immunosuppressed
patients. Candidemic patients with advanced
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age, underlying malignancy, and concomitant
non-Candida species systemic mycosis had higher
mortality. The presence of coronary artery dis-
ease appeared as a signiﬁcant predictor of unfa-
vorable short-term survival and may further help
to identify fungemic patients at increased risk of
death.
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